Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 3
1965 3
1967 1
1968 1
1969 3
1970 5
1971 13
1972 7
1973 5
1974 12
1975 18
1976 16
1977 20
1978 24
1979 18
1980 18
1981 17
1982 16
1983 27
1984 32
1985 42
1986 52
1987 77
1988 106
1989 144
1990 164
1991 204
1992 227
1993 272
1994 285
1995 329
1996 314
1997 389
1998 423
1999 524
2000 546
2001 587
2002 641
2003 752
2004 818
2005 804
2006 939
2007 1011
2008 999
2009 1088
2010 1155
2011 1273
2012 1389
2013 1452
2014 1455
2015 1509
2016 1594
2017 1757
2018 1695
2019 1750
2020 1867
2021 2141
2022 2041
2023 2016
2024 896

Text availability

Article attribute

Article type

Publication date

Search Results

32,446 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis and Treatment of Parkinson Disease: A Review.
Armstrong MJ, Okun MS. Armstrong MJ, et al. JAMA. 2020 Feb 11;323(6):548-560. doi: 10.1001/jama.2019.22360. JAMA. 2020. PMID: 32044947 Review.
Individuals with mild motor-predominant Parkinson disease (49%-53% of individuals with Parkinson disease) have mild symptoms, a good response to dopaminergic medications (eg, carbidopa-levodopa, dopamine agonists), and slower disease progression. ...CO …
Individuals with mild motor-predominant Parkinson disease (49%-53% of individuals with Parkinson disease) have mild symptoms, …
The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management.
Atri A. Atri A. Med Clin North Am. 2019 Mar;103(2):263-293. doi: 10.1016/j.mcna.2018.10.009. Med Clin North Am. 2019. PMID: 30704681 Free article. Review.
Alzheimer's disease (AD) care requires timely diagnosis and multidisciplinary management. ...When combined, pharmacologic and nonpharmacologic therapies mitigate symptoms and reduce clinical progression and care burden. AD biopathologic processes develop over decade …
Alzheimer's disease (AD) care requires timely diagnosis and multidisciplinary management. ...When combined, pharmacologic and nonphar …
Rapidly Progressive Dementia.
Day GS. Day GS. Continuum (Minneap Minn). 2022 Jun 1;28(3):901-936. doi: 10.1212/CON.0000000000001089. Continuum (Minneap Minn). 2022. PMID: 35678409 Free PMC article. Review.
PURPOSE OF REVIEW: This article presents a practical approach to the evaluation of patients with rapidly progressive dementia. RECENT FINDINGS: The approach presented in this article builds upon the standard dementia evaluation, leveraging widely available tests and emerge …
PURPOSE OF REVIEW: This article presents a practical approach to the evaluation of patients with rapidly progressive dementia. RECENT …
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.
Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, van der Flier WM, Mielke MM, Del Campo M. Teunissen CE, et al. Lancet Neurol. 2022 Jan;21(1):66-77. doi: 10.1016/S1474-4422(21)00361-6. Epub 2021 Nov 24. Lancet Neurol. 2022. PMID: 34838239 Review.
For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but recent results have shown that they could become a reality. ...Moreover, other blood-based biomarkers of neurodegeneration, such as neurofilament light chain and glial fibrillary acidic …
For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but recent results have shown that they could bec …
The characterisation of subjective cognitive decline.
Jessen F, Amariglio RE, Buckley RF, van der Flier WM, Han Y, Molinuevo JL, Rabin L, Rentz DM, Rodriguez-Gomez O, Saykin AJ, Sikkes SAM, Smart CM, Wolfsgruber S, Wagner M. Jessen F, et al. Lancet Neurol. 2020 Mar;19(3):271-278. doi: 10.1016/S1474-4422(19)30368-0. Epub 2020 Jan 17. Lancet Neurol. 2020. PMID: 31958406 Free PMC article. Review.
A growing awareness about brain health and Alzheimer's disease in the general population is leading to an increasing number of cognitively unimpaired individuals, who are concerned that they have reduced cognitive function, to approach the medical system for help. . …
A growing awareness about brain health and Alzheimer's disease in the general population is leading to an increasing number of …
Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021.
Porsteinsson AP, Isaacson RS, Knox S, Sabbagh MN, Rubino I. Porsteinsson AP, et al. J Prev Alzheimers Dis. 2021;8(3):371-386. doi: 10.14283/jpad.2021.23. J Prev Alzheimers Dis. 2021. PMID: 34101796 Review.
Alzheimer's disease is a progressive, irreversible neurodegenerative disease impacting cognition, function, and behavior. Alzheimer's disease progresses along a continuum from preclinical disease, to mild cognitive and/or behavioral impai …
Alzheimer's disease is a progressive, irreversible neurodegenerative disease impacting cognition, function, and behavio …
Neuropathology of Alzheimer's Disease.
Trejo-Lopez JA, Yachnis AT, Prokop S. Trejo-Lopez JA, et al. Neurotherapeutics. 2022 Jan;19(1):173-185. doi: 10.1007/s13311-021-01146-y. Epub 2021 Nov 2. Neurotherapeutics. 2022. PMID: 34729690 Free PMC article. Review.
The density of neuritic plaque pathology is determined by criteria defined by the Consortium to establish a registry for Alzheimer's diseases (CERAD). While these changes neuropathologically define AD, it becomes more and more apparent that the majority of patients present …
The density of neuritic plaque pathology is determined by criteria defined by the Consortium to establish a registry for Alzheimer's dise …
Rapidly progressive dementias - aetiologies, diagnosis and management.
Hermann P, Zerr I. Hermann P, et al. Nat Rev Neurol. 2022 Jun;18(6):363-376. doi: 10.1038/s41582-022-00659-0. Epub 2022 May 4. Nat Rev Neurol. 2022. PMID: 35508635 Free PMC article. Review.
Rapidly progressive dementias (RPDs) are a group of heterogeneous disorders that include immune-mediated, infectious and metabolic encephalopathies, as well as prion diseases and atypically rapid presentations of more common neurodegenerative diseases. …
Rapidly progressive dementias (RPDs) are a group of heterogeneous disorders that include immune-mediated, infectious and metabolic …
Clinical Research on Alzheimer's Disease: Progress and Perspectives.
Sun BL, Li WW, Zhu C, Jin WS, Zeng F, Liu YH, Bu XL, Zhu J, Yao XQ, Wang YJ. Sun BL, et al. Neurosci Bull. 2018 Dec;34(6):1111-1118. doi: 10.1007/s12264-018-0249-z. Epub 2018 Jun 28. Neurosci Bull. 2018. PMID: 29956105 Free PMC article. Review.
Alzheimer's disease (AD), the most common type of dementia, is becoming a major challenge for global health and social care. However, the current understanding of AD pathogenesis is limited, and no early diagnosis and disease-modifying therapy are currently availabl …
Alzheimer's disease (AD), the most common type of dementia, is becoming a major challenge for global health and social care. However, …
Parkinson's disease: Mechanisms, translational models and management strategies.
Raza C, Anjum R, Shakeel NUA. Raza C, et al. Life Sci. 2019 Jun 1;226:77-90. doi: 10.1016/j.lfs.2019.03.057. Epub 2019 Apr 10. Life Sci. 2019. PMID: 30980848 Review.
Parkinson's disease is a progressive neurodegenerative disorder. The classical motor symptoms include resting tremors, bradykinesia, rigidity and postural instability and are accompanied by the loss of dopaminergic neurons and Lewy pathology. Diminished neurotransmi …
Parkinson's disease is a progressive neurodegenerative disorder. The classical motor symptoms include resting tremors, bradyki …
32,446 results
You have reached the last available page of results. Please see the User Guide for more information.